IL17A and agammaglobulinemia: Further, production of IL-17 is defective from T cells taken from agammaglobulinemia patients that lack B cells23 and therapeutic depletion of B cells with rituximab can reduce Th17 function in the context of MS24 as well as in rheumatoid arthritis25.